Lung cancer is now the leading cause of cancer mortality in the UK, accounting for 24% of cancer deaths in men and 21% in women ([@bib42]). Worldwide rates vary markedly; overall lung cancer accounted for 18% of all cancer deaths in 2008 ([@bib17]). Rates have been impacted little by the advances in diagnosis and treatment to date, and in some groups, such as British women ([@bib42]), they continue to rise. Lung cancer is divided into two broad categories -- non-small cell (NSCLC) and small cell. More than 80% of lung cancers are NSCLC, which is comprised mostly of squamous cancers and adenocarcinomas. Key changes over the past 10 years in NSCLC include the reclassification of tumour types ([@bib41]), use of biological markers to guide certain therapies, use of adjuvant therapy after selected complete resections and advances in selection and planning for surgery and radiotherapy -- concepts that have been reviewed comprehensively elsewhere ([@bib20]). The most promise has been shown by CT-based screening, though concerns have been raised about the potential for multiple invasive tests and cost-effectiveness of the strategy ([@bib8]). Since many patients present with advanced disease surgery is often impossible, hence there is a great need for novel therapeutic agents. This is particularly important as current first line regimes add little \>2 months to the average survival ([@bib20]). In addition, many therapies are less beneficial (or indeed more harmful) in squamous tumours, such as the antifolate agent pemetrexed ([@bib49]), anti-vascular endothelial growth factor (VEGF) antibody bevacuzimab ([@bib34]) and tyrosine kinase inhibitor (TKI) gefitinib ([@bib57]). Selection for the latter drug usually also involves testing for EGFR mutation ([@bib57]), meaning that the pool of patients in whom each drug works is increasingly small. Therefore, the identification of novel biomarkers or therapeutic targets is a priority for lung cancer.

A functional vasculature contributes to tumour progression and malignant cell metastasis. Endothelial cells lining the tumour vasculature are exposed to molecular factors and mechanical forces that are absent in healthy tissue. For example, the vasculature in solid tumours is often in a hypoxic environment ([@bib14]) and is exposed to elevated the levels of hypoxically induced angiogenic factors such as VEGF ([@bib45]). Tumour vessels may also be leaky, tortuous, sometimes blind ended and have poor vascular smooth muscle and pericyte coverage ([@bib9]). As a result, the tumour endothelial transcriptome is markedly different from that in healthy tissue and provides a unique source for cancer target identification. In the last decade, attempts to identify tumour endothelial markers (TEMs) have included construction of SAGE libraries from freshly isolated endothelium ([@bib52]), use of microarray platforms ([@bib26]), proteomic analysis of freshly isolated endothelial cell membranes ([@bib26]; [@bib43]) as well as bioinformatics data mining ([@bib30]; [@bib25]). These efforts identified several targets including the EDB domain of fibronectin, a series of numbered TEMs, annexin A and recently CLEC14A reviewed in [@bib39].

Recent studies have shown that TEMs are often tissue dependent, and that endothelial transcriptomes have been documented for colon ([@bib54]), breast ([@bib11]; [@bib35]) and ovarian cancer ([@bib48]). Known TEMs are often weakly expressed in lung tumours ([@bib40]) and this prompted us to investigate TEMs in the lung. For successful expression profiling it is essential to obtain a pure endothelial population. We demonstrate in this study that rapid tissue digestion followed by magnetic bead isolation yields pure endothelial isolates. Following expression profiling of endothelial isolates from NSCLC patient samples, novel cell-surface targets of lung tumour vasculature were identified, presenting attractive potential for developing targeted therapies for lung cancer.

Materials and methods
=====================

*Ulex*-bead isolation
---------------------

Healthy and tumour lung tissue was obtained immediately following surgery with full patient consent and ethics approval (Heartlands Hospital, REC. 07/MRE08/42). Minced tissue was digested in DMEM containing 2 mg ml^−1^ collagenase type V (Sigma, Gillingham, UK), 7.4 mg ml^−1^ of actinomycin (Sigma) and 30 kU ml^−1^ of DNAse I (Qiagen, Crawley, UK) at 37^o^C. Endothelial cells were isolated from the digested cell suspension by positive selection using *Ulex europaeus* lectin-coated magnetic beads (Invitrogen, Paisley, UK).

Microarray
----------

RNA extracted from *Ulex*-bead isolated samples was converted to cRNA, then subjected to amplification and labelling. Labelled cRNA samples were then hybridised to an Agilent 4 x 44k whole human gene expression microarray (Agilent, Wokingham, UK). The Bioconductor packages preprocess Core and Limma were used to subtract background and quantile-normalise probe signal intensities prior to performing differential gene expression analyses. Principle component analysis (PCA) was performed in R.

RNA-seq
-------

Seventy-nine and 84 million paired end reads (50 bp+35 bp) were sequenced on the SOLiD4 2nd generation sequencer (Applied Biosystems, Foster City, CA, USA) for endothelium from fresh tumour and healthy tissue, respectively. Reads were mapped to the Human genome (University California Santa Cruz, version hg19) with Tophat 1.3.3 ([@bib53]). Default parameters for colour space mapping were used with the exception of the following: 1 g/---max-multihits was set to 1 to identify the single best mapped read; 2 library-type was set to fr-secondstrand to reflect the sequencing library preparation; 3 G provided Tophat with a model set of gene annotation genome positions from the Refseq hg19 transcriptome. The Tophat output bam files were sorted using samtools (Version: 0.1.8, ([@bib37])), and \'HTSeq-count\' version 0.4.7p4 ([@bib3]) was used, in conjunction with the Human transcriptome GTF Refseq version 19, to assign gene counts and produce a tab delimited file of transcript/gene counts. Differential gene expression analysis and *P*-value generation on the count data was carried out using the R Bioconductor package DESeq v1.5 ([@bib4]).

Quantitative real-time PCR
--------------------------

RNA extraction, complementary DNA preparation and quantitative real-time PCR (qPCR) were performed using LightCycler real-time quantitative PCR (Roche, Burgess Hill, UK) by following previously described methods ([@bib7]). The Primer sequences are provided in [Supplementary Table 1](#sup1){ref-type="supplementary-material"}. The double delta Ct method was used to compare the expression levels in tumour relative to healthy endothelial isolates.

Immunohistochemistry
--------------------

Immunohistochemistry of placental tissue or lung tumour sections were immunostained with antisera to the targets (all antisera from Abcam, Cambridge, UK). The sections were then visualised using ImmPRESS universal antibody kit and NovaRed chromagen (Vector labs, Burlingame, CA, USA). Finally, the sections were counterstained with Mayers hematoxylin, dehydrated and mounted in distyrene--plasticizer--xylene resin.

Functional assay with siRNA knockdown
-------------------------------------

Transfection with siRNA and functional assays were performed as previously described ([@bib7]). STEAP1 siRNA duplexes were:

D1: sense: 5′-CUAUAUUCAGAGCAAGCUATT-3′ anti-sense: 5′-UAGCUUGCUCUGAAUAUAGTG-3′

D2: sense: 5′-GAAUAAGUGGAUAGAUAUATT-3′ anti-sense: 5′-UAUAUCUAUCCACUUAUUCCA-3′ (Ambion, Chipping Norton, UK). The open area of the wound was quantified using a cell intelligence quotient analyzer or Image J software (Image J website, [rsbweb.nih.gov](http://www.rsbweb.nih.gov)). The effect of STEAP1 knockdown on Matrigel assays was analysed by Angiogenesis Analyzer for ImageJ. All images were acquired using a Leica DM IL microscope (Leica, Milton Keynes, UK) and USB 2.0 2M Xli camera (XL Imaging LLC, Carrollton, TX, USA).

Results
=======

Isolation of lung endothelium from fresh tissue
-----------------------------------------------

Previous studies have shown that a high purity of endothelial isolates can be achieved using *Ulex*-conjugated beads ([@bib31]) but has not yet been applied to human lung tissue. *Ulex* agglutinin I is a lectin that specifically binds to L-fucose residues present in glycoproteins on the human endothelial surface ([@bib27]). Here we examine this approach for the isolation of endothelium from fresh lung specimens. Fresh healthy or tumour lung tissue samples (1--3 g) were processed within 3 h post surgery. The tumour tissue was resected from the viable region of the tumour core and the patient-matched healthy tissue was resected\>10 cm away from the tumour core. Endothelial cells were positively isolated using magnetic beads coupled to *Ulex* lectin (workflow illustrated in [Figure 1A](#fig1){ref-type="fig"}). To verify endothelial enrichment, expression of the universal endothelial marker CD31 was examined by qPCR in the endothelial isolates and compared with that in the bulk tissue. A 15-fold enrichment of endothelium was achieved in the bead isolated samples when compared with whole tumour extracts. Afour-fold enrichment was seen in endothelial cells isolated from healthy lung ([Figure 1B](#fig1){ref-type="fig"}). The differing fold increase in CD31 seen in healthy and tumour samples is likely owing to the proportion of endothelial cells being higher in healthy lung (30%) than in tumours (3%--5%). RNA integrity analysis of a typical RNA isolate is shown in [Figure 1C](#fig1){ref-type="fig"}. The data confirm that the *Ulex*-bead isolation approach can effectively isolate the endothelial population from lung.

Microarray of endothelial isolates from lung cancer patients
------------------------------------------------------------

For expression profiling, a microarray analysis was performed on four pairs of NSCLC patient-matched healthy and tumour lung endothelial isolates. Clinical and pathologic data was obtained from Birmingham Heartlands Hospital ([Table 1](#tbl1){ref-type="table"}**, patients 1--4)**. A PCA plot shows variation in both tumour and healthy lung samples and between the samples of each group. This was to be expected as samples were collected and extracted from different patients and statistically significant genes are those that are consistent across replicate samples. Despite this the tumour and healthy isolates fall into two discrete groups ([Figure 2](#fig2){ref-type="fig"}).

To better understand the role of known angiogenesis-associated genes in NSCLC, a differential expression analysis was performed using the programme Limma. The analysis revealed a panel of known angiogenesis-associated genes including COL1A1, VEGF-A, TEM7, TNC, EPHB2, IL8, FGF1, ANGPTL2 and TEM8 to be elevated in lung tumour endothelium ([Table 2](#tbl2){ref-type="table"}). As tumour angiogenesis proceeds by proteolysis of the extracellular matrix ([@bib51]), elevated matrix metalloprotease (MMP) activity is associated with active angiogenesis and tumour progression. The analysis also identified a number of MMPs that are upregulated in lung tumour compared with healthy lung endothelium ([Table 3](#tbl3){ref-type="table"}).

Identification and validation of putative tumour vascular targets in NSCLC
--------------------------------------------------------------------------

For target identification, differentially expressed genes from the microarray data were filtered through several selection criteria: Log2 fold change magnitude\>1, a *P*-value\<0.5 and containing a transmembrane or signal peptide domain, which generated a list comprised of 584 genes. Twelve target candidates were chosen for further validation based on additional criteria including the level of association with endothelial cells, previously published work, sites of expression and relation to known genes with interesting functional properties ([Table 4](#tbl4){ref-type="table"}). To validate putative targets, a qPCR was performed on the four pairs of endothelial isolates used in the microarray. [Figure 3](#fig3){ref-type="fig"} shows that all candidates had elevated expression in tumour compared with that in healthy endothelium ranging from a 3-to 35-fold increase in expression.

Expression profiling of lung endothelial isolates by RNA-seq
------------------------------------------------------------

RNA-seq using deep sequencing technology provides an in-depth resolution of RNA snapshots by generating millions of reads that can be assembled and mapped to a known transcriptome, allowing the measurement of differential gene expression. RNA-seq has the advantage of querying novel transcripts and does not rely on prior knowledge and annotation. Here we used RNA-seq to verify the genes that had been identified through the microarray analysis. We note that a lower yield of RNA was obtained from healthy lung tissue compared with that from tumour. This was possibly owing to the endothelial cells in healthy lung tissue being in a quiescent state compared with the active endothelium in tumours. For this reason, endothelial RNA isolated from three healthy lung samples (pooled; [Table 1](#tbl1){ref-type="table"}**, patients 5--7**) and one tumour lung tissue ([Table 1](#tbl1){ref-type="table"}**, patient 6**) were sequenced as one healthy and one tumour sample on a SOLiD4 sequencer. The differential gene expression analysis of the RNA-seq data was performed using the DESeq v1.5 package ([@bib4]). The analysis confirmed most of the unregulated angiogenesis-associated genes, MMPs and putative targets identified through the microarray analysis ([Figure 4](#fig4){ref-type="fig"}). Analysis of the RNA-seq data alone generated a list of 477 genes with the same criterion used in the microarray analysis for target identification. The intersection of the microarray and RNA-seq gene pools comprises a list of 122 genes, which provides a rich source for target identification ([Supplementary Table 2](#sup1){ref-type="supplementary-material"}). The discrepancy between the two analyses is likely owing to the cancer type (squamous *vs*. adeno) and the individual patient variability.

Expression of TEM candidates in angiogenic tissue and lung cancer
-----------------------------------------------------------------

To further validate the candidate targets, we investigated protein expression by immunohistochemistry. We have previously shown that placental vasculature is a rich source of endothelial gene expression. Thus, immunohistochemical staining was performed first on the human placental tissue using antibodies to the lung TEM targets. Amongst the twelve targets, six genes: ROS1, PCDH7, BIRC5, STEAP1, GJB2 and PROM2 showed expression in human placental vessels ([Supplementary Figure 1](#sup1){ref-type="supplementary-material"}). The tumour and healthy lung tissue was then immunostained and these six candidates are indeed overexpressed in the lung tumour vessels, whereas absent or at a low level in the healthy lung tissue ([Figure 5](#fig5){ref-type="fig"}). Some of the targets were not restricted to the tumour endothelium; for example, ROS1 and STEAP1 also showed positive expression on some tumour cells or macrophages and this may be beneficial for developing drugs targeting the tumour and its vasculature simultaneously. It is also worth mentioning that other target candidates should not be completely eliminated for further investigation simply owing to the lack of antibody reactivity in immunochemistry.

Expression of STEAP1 in lung cancer
-----------------------------------

We then focused on the top-ranked target STEAP1. To confirm whether STEAP1 is differentially expressed in the endothelium within the healthy and tumour lung tissue, an expression profiling was carried out on human lung cancer tissues by immunohistochemistry. Eighty-two patients were examined ([Table 5](#tbl5){ref-type="table"}). The intensity of the signal was classified as absent, low, medium or high. Representative images of STEAP1 staining in lung cancer are shown in [Figure 6A](#fig6){ref-type="fig"}. From the 82 cases examined, a clear overexpression of STEAP1 in tumour vessels was observed; for example 45% of the vessels highly expressed STEAP1 in lung cancer *vs* only 5% in matching healthy lung. The proportion of vessels that are 'low\' and 'no expression\' of STEAP1 was 77% in healthy lung, but only 14% in lung tumours ([Figure 6B](#fig6){ref-type="fig"}). These data confirm that STEAP1 is differentially expressed between the tumour and healthy lung vasculature and presents a possible vascular target for lung cancers.

Function of STEAP1 in endothelial cells
---------------------------------------

We next used siRNA knockdown to seek a function of STEAP1 in the endothelial cells. STEAP1 protein expression was efficiently knocked down by two independent siRNA duplexes ([Figure 7A](#fig7){ref-type="fig"}). Migration of HUVEC after STEAP1 knockdown was compared with that of mock and negative siRNA-transfected controls in a scratch-wound assay. At 24 h, control wounds showed 60% closure, whereas in STEAP1 knockdown cells the wound had only closed by 35%--40% ([Figure 7B and C](#fig7){ref-type="fig"}). STEAP1 knockdown also compromised tube formation on Matrigel. Tubes showed a significant decrease in mesh size compared with controls ([Figure 7D and E](#fig7){ref-type="fig"}).

Discussion
==========

The ineffectiveness of current treatments for NSCLC prompted the search for alternatives. Although TKIs of EGFR initially showed promising outcomes in several trials, resistance developed in all the patients ([@bib38]). Antiangiogenic/anti-tumour vascular therapy remains a viable alternative ([@bib55]). VEGF (receptor) blockers have been used to treat NSCLC patients in early clinical trials; however, concerns have arisen from the limited efficacy in achieving tumour regression and the tendency to develop resistance ([@bib44]). In addition, the lack of effective biomarkers for patient pre-treated selection, emphasises the need for novel targets and biomarkers. Our study describes the first molecular profiling of endothelium from NSCLC patient tissue.

A major obstacle that hinders the expression profiling of *in vivo* endothelium is the challenge to obtain pure endothelial isolates. Favre *et al* described attempts for mouse lung endothelial isolates, using the unpurified sample as the control, aimed at identifying endothelial specific genes ([@bib16]). An effort to isolate mouse endothelium from a Lewis lung carcinoma tumour model was reported by [@bib1]; however, the isolated endothelial cells were subjected to *in vitro* culture and only the characterised angiogenesis genes were investigated ([@bib1]). In this study, we demonstrate that the *Ulex*-bead isolation approach has proven to be an effective approach to obtain a pure endothelial population from the human lung. The purity of the endothelial isolates allows for the first time to precisely document the transcriptome of the lung vasculature using microarray analysis and deep sequencing platforms.

Our microarray analysis of endothelial isolates from cancer patients identified a panel of angiogenesis-associated genes and MMPs elevated in tumour endothelium, which have potential to be biomarkers for NSCLC. The elevated MMP2 expression is in agreement with a reported increased MMP2 level in serum that was shown to be a predictor of metastasis in NSCLC patients ([@bib23]). MMP2 and MMP9 have also been reported to associate with tumour grade in various solid tumours ([@bib33]). The expression of MMP7 and MMP9 were previously found to be significantly upregulated in NSCLC compared with that of healthy lung and benign lung tumours ([@bib46]). Although clinical trials investigating inhibitors targeting multiple MMPs yielded limited efficacy ([@bib24]; [@bib19]), possibilities remain to design drugs that are more specific to those highly expressed MMPs in NSCLC.

RNA-seq using deep sequencing technology has been intensively applied to molecular profiling of many tissue types and cell populations from different species ([@bib22]; [@bib56]). This work is the first description of RNA-seq for profiling the endothelium from human lung cancer. Further, cross referencing the microarray data identified 122 genes as lung vascular target candidates. Immunohistochemical analysis confirmed PCHD7, STEAP1, ROS1, BIRC5, GJB2 and RPOM2 to be novel tumour vascular targets in NSCLC.

STEAP1 was the first member of a family of metalloreductases described as a cell-surface antigen in prostate tissue ([@bib29]; [@bib59]). High STEAP1 expression has been found in prostate, breast, bladder, colon and ovarian carcinomas and in Ewing\'s sarcoma, ([@bib21]) whereas low or absent in healthy human tissues, suggesting that STEAP1 may be a wide ranging tumour antigen ([@bib29]). [@bib2] showed that STEAP1 peptides can be used to stimulate CD8^+^ T cells, suggesting that STEAP1 may be a useful target for cancer immunotherapy. Indeed, Maria de la Luz and colleagues also showed the efficacy of a vaccine against STEAP1 in prophylactic and therapeutic tumour models ([@bib18]). To date, expression of STEAP1 in endothelium has not been described. Our data have shown for the first time that STEAP1 expression is upregulated in endothelial cells in the vessels of human lung tumours.

PCDH7 belongs to the protocadherin gene family and encodes a single-pass transmembrane protein. First reported in 1998, study of PCDH7 has concentrated on neuronal function ([@bib60]; [@bib36]; [@bib13]), and a role in endothelium or lung cancer has not been explored. An exception was a genome-wide genotyping of the frozen tumour tissue from NSCLC patients that identified five nucleotide polymorphisms (SNPs) located in PCDH7 that are prognostic for the overall survival in early-stage NSCLC ([@bib28]). ROS1 is a proto-oncogene and highly expressed in a variety of tumour cell lines ([@bib12]; [@bib50]). ROS1 belongs to the sevenless subfamily of tyrosine kinase receptors and remains an orphan receptor. Recently, chromosomal rearrangement of ROS1 was detected in a subpopulation of NSCLC patients ([@bib10]; [@bib32]). Despite intensive study of ROS1 in lung cancer, there has been no previous report of its expression in the tumour endothelium. BIRC5 or survivin, belongs to a family of inhibitors of apoptosis. BIRC5 inhibits the caspase activation regulating apoptosis. Disruption of the BIRC5 signalling pathway leads to tumour cell apoptosis and growth delay. BIRC5 protein is often present in tumour cells and fetal tissues but has rarely been described in the healthy tissue ([@bib47]). GJB2 is a transmembrane protein that belongs to the connexin family. Connexins have a role in many physiological processes and embryonic development including the microvasculature. Defects in GJB2 lead to the most common form of congenital deafness ([@bib6]). Thus, most GJB2 studies have centred on this pathology. Nevertheless, a recent study reported the expression of GJB2 in lymphatic endothelium in the mouse embryo, and that the deletion of GJB2 in mice disrupted the development of lymphatic vessels and was embryonic lethal ([@bib15]). PROM2 is a multi-pass membrane protein and belongs to the prominin family of pentaspan membrane glycoproteins. PROM2 is at present comparatively uncharacterised.

Low shear stress and turbulent flow are mechanical factors that regulate endothelial gene expression ([@bib58]). Around 600 genes are regulated by shear stress in the endothelial cell ([@bib5]; [@bib40]). Like the previously described TEMs CLEC14A and Robo4, STEAP1, PCDH7 and BIRC5 are all upregulated in the endothelium exposed to reduced shear stress (Bicknell et al, unpublished data). Reduced blood flow and shear stress may account for their expression on tumour vessels.

To conclude, our work not only enhances our knowledge of proteins that are differentially expressed on the lung tumour endothelium but has also identified several promising biomarkers/targets for future investigation. Cell-surface expression of some of these targets, for example STEAP1, will facilitate the pre-clinical validation with antibodies. Further work is needed to characterise their functions and their roles in the endothelial biology and angiogenesis in the lung.
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![**A *Ulex*-coated magnetic bead isolation achieved substantial endothelial enrichment and gave good quality RNA.** (**A**) The workflow of the main steps in *Ulex*-bead isolation of endothelial cells from healthy/tumor lung tissue. (**B**) Confirmation of endothelial enrichment using the *Ulex*-beads approach. Real-time PCR using a primer set for the endothelial marker CD31 was performed on the bead isolated endothelial cells and bulk tissue. Expression of CD31 in the bead isolated sample was normalised to that in the bulk tissue (*n*=3). (**C**) Good quality RNA (RIN\>7) was obtained from *Ulex*-bead isolated endothelial cells from healthy and tumour lung tissue. ECs=Endothelial cells.](bjc2014626f1){#fig1}

![**Principle component analysis plot of microarray of the four pairs of healthy and tumour lung endothelial isolates.** A PCA plot showing that the endothelial transcriptomes of healthy and tumour lung show a clear difference. The separation between healthy and tumour lung endothelium was highlighted by dotted lines.](bjc2014626f2){#fig2}

![**Validation of putative lung vascular targets by qPCR.** Quantitative real-time PCR validation of tumour vascular target candidates in the endothelial cells isolated from the healthy and tumour lung tissue. Flotillin 2 was used as the house keeping gene to which the data was normalised. The double delta Ct method was used to compare the expression levels in tumour relative to healthy endothelial isolates.](bjc2014626f3){#fig3}

![**Confirmation of upregulated angiogenesis-associated genes, MMP and putative vascular targets in lung cancer by RNA-seq.** Differential gene expression analysis of RNA-seq data confirmed a panel of elevated angiogenesis-associated genes, MMP genes and lung cancer vascular target candidates identified through microarray analysis.](bjc2014626f4){#fig4}

![**Validation of putative lung vascular targets by immunohistochemistry.** Identified putative lung TEMs were validated by immunohistochemistry. Representative immunohistochemistry for lung vascular target candidates on the healthy and tumour lung tissue.](bjc2014626f5){#fig5}

![**Expression profiling of STEAP1 expression in clinical lung cancer samples.** (**A**) Representative images of STEAP1 in healthy (i--ii) and tumour (iii--vi) lung tissue; expression level classified as no expression (i), low (ii--iii), medium (iv) and high (v--vi). Images were acquired using an optical microscope at a magnification of × 20. (**B**) Expression profiling of STEAP1 in clinical samples by immunohistochemistry (*n*=82).](bjc2014626f6){#fig6}

![**Functional analysis of STEAP1 in endothelial cells.** (**A**) Western blot showing that two independent siRNA duplexes efficiently knock down the STEAP1 protein in HUVEC. Tubulin was used as a loading control. STEAP1 appears as two bands, the 65-kDa glycosylated mature protein and the 30-kDa unglycosylated precursor. (**B**--**C**) Scratch-wound assay and (**D**--**E**) Matrigel tube forming assay in HUVEC transfected with mock, negative control or STEAP1 siRNA duplexes (± s.e.m.).](bjc2014626f7){#fig7}

###### Clinical-pathological data of lung cancer patients used in the genomic analysis

  **ID**   **Age**    **Gender**  **Pack years smoked**    **Histology of tumour**   **Tumour stage**   **Application**
  -------- --------- ------------ ----------------------- ------------------------- ------------------ -----------------
  1        65             M       15                              Squamous                T1N0M0          Microarray
  2        71             M       40                              Squamous                T1N0M0          Microarray
  3        63             F       17                              Squamous                T1N1M0          Microarray
  4        67             M       50                              Squamous                T3N0M0          Microarray
  5        73             F       25                                Adeno                 T2N0M0            RNA-Seq
  6        83             M       35                                Adeno                 T2N1M0            RNA-Seq
  7        52             M       25                                Adeno                 T2N1M0            RNA-Seq

###### Upregulated angiogenesis-associated genes in lung cancer

  **Gene ID**                             **Gene symbol**   **GenBank accession no.**  **LogFC**   **P-value**
  -------------------------------------- ----------------- --------------------------- ----------- -------------
  Collagen, type I, alpha 1                   COL1A1                NM_000088          5.11        0.00
  Vascular endothelial growth factor A        VEGF-A              NM_001025366         2.59        0.00
  Plexin domain containing 1               PLXDC1(TEM7)             NM_020405          2.04        0.01
  Tenascin C                                    TNC                 NM_002160          1.95        0.01
  Eph receptor B2                              EPHB2                NM_004442          1.76        0.00
  Interleukin 8                                 IL8              ENST00000401931       1.34        0.16
  Fibroblast growth factor 1 (Acidic)          FGF1                 NM_000800          0.82        0.08
  Angiopoietin-like 2                         ANGPTL2               NM_012098          0.69        0.40
  Anthrax toxin receptor 1                 ANTXR1(TEM8)             NM_032208          0.65        0.15

Abbreviation: LogFC=log2 fold change; TEM=tumour endothelial marker. Differential expression analysis of microarray data for the identification of elevated known angiogenesis-associated genes. Listed genes were ranked by LogFC in descending order.

###### Upregulated matrix metallopeptidases in lung cancer

  **Gene ID**                   **Gene Symbol**   **GenBank accession no.**  **LogFC**   ***P*****-value**
  ---------------------------- ----------------- --------------------------- ----------- -------------------
  Matrix metallopeptidase 11         MMP11                NM_005940          4.10        0.00
  Matrix metallopeptidase 9          MMP9                 NM_004994          4.00        0.00
  Matrix metallopeptidase 12         MMP12                NM_002426          3.80        0.00
  Matrix metallopeptidase 7          MMP7                 NM_002423          3.29        0.17
  Matrix metallopeptidase 1          MMP1                 NM_002421          2.49        0.05
  Matrix metallopeptidase 3          MMP3                 NM_002422          1.81        0.02
  Matrix metallopeptidase 10         MMP10                NM_002425          1.74        0.12
  Matrix metallopeptidase 14         MMP14                NM_004995          1.55        0.00
  Matrix metallopeptidase 13         MMP13                NM_002427          1.21        0.04
  Matrix metallopeptidase 2          MMP2                 NM_004530          1.03        0.12

Abbreviations: Log FC=log fold change; MMP=matrix metalloprotease. Differential expression analysis of microarray data for the identification of elevated matrix metallopeptidases. Listed genes were ranked by logFC in descending order.

###### Putative vascular targets in lung cancer

  **Gene ID**                                                    **Gene Symbol**   **GenBank accession no.**  **LogFC**   ***P*****-value**   **TM**
  ------------------------------------------------------------- ----------------- --------------------------- ----------- ------------------- --------
  Six transmembrane epithelial antigen of the prostate 1             STEAP1                NM_012449          4.19        0.00                6
  Synaptotagmin Xii                                                   SYT12                NM_177963          4.16        0.00                1
  Gap junction protein, *β* 2, 26Kda                                  GJB2                 NM_004004          4.13        0.00                4
  Solute Carrier organic anion transporter family, member 1B3        SLCO1B3               NM_019844          3.65        0.00                11
  Baculoviral Iap Repeat containing 5                                 BIRC5              NM_001012271         3.45        0.00                0
  Protocadherin 7                                                     PCDH7                NM_002589          2.29        0.00                1
  Prominin 2                                                          PROM2              NM_001165978         2.05        0.00                6
  Plexin Domain Containing 1                                      PLXDC1(TEM7)             NM_020405          2.04        0.01                1
  Bmp and activin membrane-bound inhibitor homologue                  BAMBI                NM_012342          1.99        0.00                1
  Lemur tyrosine kinase 3                                             LMTK3              NM_001080434         1.94        0.07                2
  Trophoblast glycoprotein                                            TPBG                 NM_006670          1.48        0.03                1
  C-Ros oncogene 1 , receptor tyrosine kinase                         ROS1              ENST00000403284       1.39        0.22                1

Abbreviations: Log FC, log fold change; TEM, tumour endothelial marker. Differential expression analysis of microarray data for the identification of putative vascular targets for lung cancer. Listed genes were ranked by logFC in descending order.

###### Clinical characteristics of lung cancer patients for STEAP1 profiling

                                  **Patients (*****n***)   **%**
  ------------------------------ ------------------------ -------
  Age                                    63.8±9.5             
  **Sex**                                                 
  Male                                      64              78%
  Female                                    18              22%
  **Histology**                                           
  Squamous cell carcinoma                   47             57.3%
  Adenocarcinomas                           19             23.2%
  Large cell carcinoma                      5              6.1%
  Bronchioloalveolar carcinoma              7              8.5%
  Carcinosarcoma                            2              2.4%
  **Clinical stage**                                      
  I                                         34             41.5%
  II                                        35             42.7%
  III                                       13             15.8%
